Humacyte Analyst Ratings
Humacyte Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 27.66% | Piper Sandler | $3.5 → $3 | Maintains | Neutral |
| 09/21/2023 | 197.87% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 08/31/2023 | 155.32% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 08/24/2023 | 155.32% | Cantor Fitzgerald | → $6 | Reiterates | Overweight → Overweight |
| 08/15/2023 | 580.85% | Benchmark | → $16 | Reiterates | Buy → Buy |
| 06/22/2023 | 155.32% | Cantor Fitzgerald | → $6 | Initiates Coverage On | → Overweight |
| 06/12/2023 | 580.85% | Benchmark | → $16 | Reiterates | Buy → Buy |
| 03/27/2023 | 580.85% | Benchmark | → $16 | Reiterates | → Buy |
| 07/18/2022 | 325.53% | BTIG | $12 → $10 | Maintains | Buy |
| 10/29/2021 | 623.4% | Cowen & Co. | → $17 | Initiates Coverage On | → Outperform |
| 09/24/2021 | 580.85% | Oppenheimer | → $16 | Initiates Coverage On | → Outperform |
| 09/22/2021 | 708.51% | BTIG | → $19 | Initiates Coverage On | → Buy |
| 09/16/2021 | 623.4% | Piper Sandler | → $17 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/10/2023 | 27.66% | 派珀·桑德勒 | 3.5 美元 → 3 美元 | 维护 | 中立 |
| 09/21/2023 | 197.87% | 坎托·菲茨杰拉德 | → 7 美元 | 重申 | 超重 → 超重 |
| 08/31/2023 | 155.32% | 坎托·菲茨杰拉德 | → 6 美元 | 重申 | 超重 → 超重 |
| 08/24/2023 | 155.32% | 坎托·菲茨杰拉德 | → 6 美元 | 重申 | 超重 → 超重 |
| 08/15/2023 | 580.85% | 基准 | → 16 美元 | 重申 | 购买 → 购买 |
| 06/22/2023 | 155.32% | 坎托·菲茨杰拉德 | → 6 美元 | 启动覆盖范围开启 | → 超重 |
| 06/12/2023 | 580.85% | 基准 | → 16 美元 | 重申 | 购买 → 购买 |
| 03/27/2023 | 580.85% | 基准 | → 16 美元 | 重申 | → 购买 |
| 07/18/2022 | 325.53% | BTIG | 12 美元 → 10 美元 | 维护 | 买 |
| 10/29/2021 | 623.4% | Cowen & Co. | → 17 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 9 月 24 日 | 580.85% | 奥本海默 | → 16 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 9 月 22 日 | 708.51% | BTIG | → 19 美元 | 启动覆盖范围开启 | → 购买 |
| 09/16/2021 | 623.4% | 派珀·桑德勒 | → 17 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for Humacyte (HUMA)?
Humacyte (HUMA) 的目标价格是多少？
The latest price target for Humacyte (NASDAQ: HUMA) was reported by Piper Sandler on November 10, 2023. The analyst firm set a price target for $3.00 expecting HUMA to rise to within 12 months (a possible 27.66% upside). 8 analyst firms have reported ratings in the last year.
派珀·桑德勒于2023年11月10日公布了Humacyte（纳斯达克股票代码：HUMA）的最新目标股价。该分析公司将目标股价定为3.00美元，预计HUMA将在12个月内升至12个月内（可能上涨27.66％）。去年有8家分析公司公布了评级。
What is the most recent analyst rating for Humacyte (HUMA)?
分析师对Humacyte（HUMA）的最新评级是多少？
The latest analyst rating for Humacyte (NASDAQ: HUMA) was provided by Piper Sandler, and Humacyte maintained their neutral rating.
派珀·桑德勒对Humacyte（纳斯达克股票代码：HUMA）的最新分析师评级由派珀·桑德勒提供，Humacyte维持中性评级。
When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?
Humacyte（HUMA）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表、与Humacyte的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Humacyte的最新评级是在2023年11月10日发布的，因此您应该预计下一个评级将在2024年11月10日左右公布。
Is the Analyst Rating Humacyte (HUMA) correct?
分析师对 Humacyte (HUMA) 的评级正确吗？
While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a maintained with a price target of $3.50 to $3.00. The current price Humacyte (HUMA) is trading at is $2.35, which is out of the analyst's predicted range.
尽管评级是主观的并且会发生变化，但最新的Humacyte（HUMA）评级保持不变，目标股价为3.50美元至3.00美元。Humacyte（HUMA）目前的交易价格为2.35美元，超出了分析师的预期区间。